Edgewise Therapeutics (EWTX) PT Raised to $25 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts EWTX Hot Sheet
Price: $38.11 -2.03%
Rating Summary:
12 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
12 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
JPMorgan analyst Tessa Romero raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $25.00 (from $24.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $110 at Jefferies
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $107 at Baird amid partial clinical hold
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
